Genmab A/S Stock

Genmab A/S Capital Intensity

The Capital Intensity Ratio of Genmab A/S (GMAB.CO) as of Aug 19, 2026 is 346.05 %. In the previous year, Capital Intensity Ratio was 203.74 % — a change of 69.85% (higher).

Capital Intensity

346.05 %

YoY

69.85%

Last updated:

Capital Intensity Ratio of Genmab A/S is 2026 346.05 % . Capital Intensity Ratio of Genmab A/S was 2025 203.74 % . It decreases by 69.85% higher compared to the previous year.
Access this data via the Eulerpool API

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Capital Intensity Ratio of Genmab A/S is 346.05 % in 2026.

Capital Intensity Ratio of Genmab A/S changed from 203.74 % to 346.05 %, representing a 69.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Genmab A/S with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

Profitability — Genmab A/S

All Key Metrics — Genmab A/S